Cross-Sector entity
Every one of those 1 sits in a single category, market-trends. Center for Drug Evaluation is most often covered alongside HMI-115, which appears in 1 of these 1 story. Each carries 10 original sources on average. We currently track 1 Cross-Sector story that mention Center for Drug Evaluation, all published on March 25, 2026.
1 verified story tracked
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Center for Drug Evaluation is most often covered alongside HMI-115, which appears in 1 of these 1 story. Each carries 10 original sources on average. We currently track 1 Cross-Sector story that mention Center for Drug Evaluation, all published on March 25, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Center for Drug Evaluation. Shared-story counts are live from our verified record — not editorial picks.
Phase III Initiation
First patient dosed at Peking Union Medical College Hospital in China.
Regulatory Designations
FDA grants Fast Track and NMPA grants Breakthrough Therapy status.
Phase II Data Publication
Results showing efficacy without hormonal side effects published in The Lancet.
Hope Medicine Inc. has initiated Phase III dosing for HMI-115, the first non-hormonal monoclonal antibody for endometriosis to reach this clinical stage. This milestone, supported by FDA Fast Track and NMPA Breakthrough designations, signals a potential shift away from traditional hormone-suppressing therapies in women's health.
Source: Woonsocketcall · Laotian Times
